Intellia Therapeutics, Inc.
http://www.intelliatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intellia Therapeutics, Inc.
What To Look Out For At ESC 2024
Full data on heart disease products from Alnylam, Bayer and others will take center stage at the cardiology meeting later this month.
Intellia Becomes First To Show Potential For CRISPR Therapy Re-Dosing
The company presented data showing it is possible to safely and effectively re-dose its ATTR amyloidosis CRISPR/Cas9-based therapy.
Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.
Intellia Builds Case For NTLA-2002’s Functional Cure In Angiodema
The hereditary angioedema candidate could become the first ever in vivo gene-editing therapy – but whether it will truly transform treatment remains to be seen.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- ADMET
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Caribou Biosciences
- eXtellia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice